NCT03380923

Brief Summary

The PHITE collaborative team, consisting of Tim Broderick, MD (Overall PI), Wright State University (WSU); Marcas Bamman, PhD (Site PI), The University of Alabama at Birmingham (UAB); and Ron Evans, PhD and Joe Ecker, PhD, Salk Institute for Biological Studies, are working with funding from the US Department of Defense (DoD), Office of Naval Research (ONR), to explore the link between physical training and epigenetics. This is a key interest area for the DoD ONR because it provides high-impact optimization of force readiness in warfighters with diverse backgrounds. The term epigenetics refers to heritable changes in gene expression (active versus inactive genes) that does not involve changes to the underlying DNA sequence; a change in phenotype (the set of observable characteristics of an individual resulting from the interaction of its genotype with the environment) without a change in genotype (the genetic constitution of an individual organism) . This in turn affects how cells read the genes. Epigenetic change is a regular and natural occurrence but can also be influenced by several factors including age, the environment/lifestyle, and disease state. Epigenetic modifications can manifest as commonly as the manner in which cells terminally differentiate to end up as skin cells, liver cells, brain cells, etc. New and ongoing research is continuously uncovering the role of epigenetics in a variety of human conditions. This study is designed to assess whether epigenetics is a primary mechanism modulating how individuals adapt to specific exercise training prescriptions designed to produce a warfighter phenotype. The PHITE team is organized around a shared test population of human subjects for which UAB will oversee recruitment, training, testing, and sampling. Healthy but untrained volunteers, both men and women, 18-27 y of age-phenotypical of the US warfighter-will participate in a 12-wk, two-arm, single-blind, randomized, exercise dose-response trial comparing two intensities of combined training: Moderate-Intensity vs. High-Intensity. Biospecimens are collected before and after an acute exercise bout in the pre-training state, and again after 12 weeks of 3 d/wk combined exercise training. Numerous phenotyping assessments are collected before after the 12-week intervention period to associate exercise training outcomes with molecular changes in the skeletal muscle and blood biospecimens.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
239

participants targeted

Target at P75+ for not_applicable healthy

Timeline
Completed

Started Feb 2017

Longer than P75 for not_applicable healthy

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 23, 2017

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

November 15, 2017

Completed
1 month until next milestone

First Posted

Study publicly available on registry

December 21, 2017

Completed
3.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 30, 2021

Completed
1 day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 31, 2021

Completed
Last Updated

October 7, 2021

Status Verified

October 1, 2021

Enrollment Period

4.4 years

First QC Date

November 15, 2017

Last Update Submit

October 5, 2021

Conditions

Keywords

epigeneticsexercise dose-responseinter-individual response heterogeneityexercise training adaptations

Outcome Measures

Primary Outcomes (2)

  • Change in muscle mass

    Muscle mass is assessed using DXA (dual-energy X-ray absorptiometry)

    16 weeks

  • Change in cardiorespiratory fitness (VO2max)

    VO2max is assessed using via indirect calorimetry during a graded cycle ergometry protocol

    16 weeks

Study Arms (2)

Moderate Intensity (MOD)

EXPERIMENTAL

Endurance Training (ET): 3 d/wk x 30 minutes (min) of steady-state, moderate-intensity exercise on a treadmill or stationary cycle ergometer at target heart rate (HR) = 65-75% of maximum oxygen consumption rate (VO2max). The two modes (treadmill, bicycle) are offered for variety, and each subject is required to use each mode at least 1 d/wk to prevent bias. Resistance training (RT): 2 d/wk consisting of a prescription engaging all major muscle groups in 10 movements. Excluding abdominal crunches, target intensity is 12 repetitions/set to volitional fatigue. Subjects complete 3 sets of each movement, with \~60 seconds (s) rest between sets. For each movement, resistance increases when 14 repetitions are achieved for 2 of 3 sets. HR is monitored throughout each session and stored for analysis.

Behavioral: Moderate Intensity

High Intensity (HI)

EXPERIMENTAL

RT: The 2 d/wk RT prescription differs from the MOD arm only in intensity and rest intervals. The same approach to progression applies, but HI RT intensity targets 8-10 repetitions per set; thus, resistance loads increase when 10 repetitions are achieved for 2 of 3 sets. The HI arm performs "superset" training, pairing movements stressing different muscle groups, with only 30-45 s between. ET: In lieu of steady-state endurance exercise, the HI arm performs high-intensity interval training (HIIT) 3 d/wk using a mix of challenging, explosive movements at maximal intensity. 10 x 30 s maximal intensity intervals are separated by 30 s rest intervals. HR is monitored throughout each session and stored for analysis.

Behavioral: High Intensity

Interventions

Exercise prescription intensity is moderate

Also known as: MOD
Moderate Intensity (MOD)
High IntensityBEHAVIORAL

Exercise prescription intensity is high

Also known as: HI
High Intensity (HI)

Eligibility Criteria

Age18 Years - 27 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy 18-27 year olds who are not in the US armed forces

You may not qualify if:

  • History of regular endurance or resistance training in past 12 months
  • BMI\>30
  • Inability to tolerate intense exercise
  • Diabetes
  • Uncontrolled hypertension
  • Unstable or exercise induced angina pectoris or myocardial ischemia
  • Vascular disease
  • Neurologic disease
  • Musculoskeletal disorder
  • Mental health disorder
  • Any chronic or infectious disease that would preclude full participation
  • Lidocaine allergy
  • Pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Alabama at Birmingham, Center for Exercise Medicine

Birmingham, Alabama, 35205, United States

Location

Study Officials

  • Marcas Bamman, PhD

    University of Alabama at Birmingham

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
Outcomes assessors analyzing biospecimen samples are blinded to the arm to which each participant has been randomly assigned when doing analysis. Investigators are blinded to each participant's randomized assignment.
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Model Details: Randomized to moderate intensity vs. high-intensity exercise training prescription.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Site Principle Investigator

Study Record Dates

First Submitted

November 15, 2017

First Posted

December 21, 2017

Study Start

February 23, 2017

Primary Completion

July 30, 2021

Study Completion

July 31, 2021

Last Updated

October 7, 2021

Record last verified: 2021-10

Data Sharing

IPD Sharing
Will share

De-identified data will be available 12 months after completion of the trial. Data will be publicly available indefinitely. Data will include phenotyping test results and molecular mapping results.

Shared Documents
STUDY PROTOCOL
Time Frame
De-identified data will be available 12 months after completion of the trial. Data will be publicly available indefinitely.

Locations